首页> 外文期刊>Inorganica Chimica Acta >Diphosphinoazine rhodium(III) and iridium(III) octahedral complexes
【24h】

Diphosphinoazine rhodium(III) and iridium(III) octahedral complexes

机译:二膦嗪铑(III)和铱(III)八面体络合物

获取原文
获取原文并翻译 | 示例
       

摘要

Rhodium(III) and iridium(III) octahedral complexes of general formula [MCl3{R2PCH2C(Bu-t)=NN=C (Bu-t)CH2PR2}] (M = Rh, Ir; R = Ph, c-C6H11, Pr-i, Bu-t; not all the combinations) were prepared either from the corresponding diphosphinoazines and RhCl3 center dot 3H(2)O or by the oxidation of previously reported bridging complexes [{MCl(1,2-eta:5,6-eta-CH=CHCH2CH2CH=CHCH2CH2)}(2){mu-R2PCH2C(Bu-t)=NN=C( Bu-t) CH2PR2}] with chlorine-containing solvents. Depending on the steric properties of the ligands, complexes with facial or meridional configuration were obtained. Crystal and molecular structures of three facial and two meridional complexes were determined by X-ray diffraction. Hemilability of ligand in the complex fac- [RhCl3{(C6H11)(2)PCH2C(Bu-t)=NN=C(Bu-t)CH2P(C6H11)(2)}] consisting in reversible decoordination of the phosphine donor group in the six-membered ring was observed as the first step of isomerization between fac and mer isomers.
机译:通式[MCl3 {R2PCH2C(Bu-t)= NN = C(Bu-t)CH2PR2}]的铑(III)和铱(III)八面体络合物(M = Rh,Ir; R = Ph,c-C6H11, Pr-i,Bu-t;并非所有组合)都是由相应的二膦基嗪和RhCl3中心点3H(2)O或通过先前报道的桥连络合物[{MCl(1,2-eta:5, 6-η-CH= CHCH2CH2CH = CHCH2CH2)}(2){mu-R2PCH2C(Bu-t)= NN = C(Bu-t)CH2PR2}]。取决于配体的空间性质,获得具有面部或子午构型的复合物。通过X射线衍射确定了三个面部和两个子午线络合物的晶体和分子结构。配体fac- [RhCl3 {(C6H11)(2)PCH2C(Bu-t)= NN = C(Bu-t)CH2P(C6H11)(2)}]中的配体半球形,包括膦供体基团的可逆配位观察到六元环中的β-环糊精是fac和mer异构体之间异构化的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号